CA2273622C - Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales - Google Patents

Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales Download PDF

Info

Publication number: CA2273622C
Authority: CA; Canada
Prior art keywords: peptide; tsxv; motif; containing peptide; excitotoxicity
Prior art date: 1999-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2273622A

Other languages

English (en)

Other versions

CA2273622A1 (fr

Inventor

Michael Tymianski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NoNO Inc

Original Assignee

NoNO Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-02

Filing date

1999-06-02

Publication date

2012-03-20

1999-06-02 Application filed by NoNO Inc filed Critical NoNO Inc

1999-06-02 Priority to CA2273622A priority Critical patent/CA2273622C/fr

2000-12-02 Publication of CA2273622A1 publication Critical patent/CA2273622A1/fr

2002-07-30 Priority to US10/208,374 priority patent/US7595297B2/en

2004-08-31 Priority to US10/930,192 priority patent/US7510824B2/en

2007-08-20 Priority to US11/894,818 priority patent/US7846897B2/en

2009-02-25 Priority to US12/392,988 priority patent/US8071548B2/en

2009-09-11 Priority to US12/557,884 priority patent/US8648043B2/en

2011-10-31 Priority to US13/286,071 priority patent/US20120302504A1/en

2012-03-20 Application granted granted Critical

2012-03-20 Publication of CA2273622C publication Critical patent/CA2273622C/fr

2014-05-15 Priority to US14/279,243 priority patent/US20150190459A1/en

2016-10-12 Priority to US15/292,062 priority patent/US20170239316A1/en

2018-04-18 Priority to US15/956,563 priority patent/US20180369319A1/en

2019-06-02 Anticipated expiration legal-status Critical

2019-09-21 Priority to US16/578,318 priority patent/US20200222492A1/en

Status Expired - Lifetime legal-status Critical Current

Links

108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract description 65
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract description 64
230000011664 signaling Effects 0.000 title description 11
230000005764 inhibitory process Effects 0.000 title description 4
230000003961 neuronal insult Effects 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
230000003492 excitotoxic effect Effects 0.000 claims abstract description 24
230000000254 damaging effect Effects 0.000 claims abstract description 22
231100000063 excitotoxicity Toxicity 0.000 claims abstract description 21
241000124008 Mammalia Species 0.000 claims abstract description 20
208000014674 injury Diseases 0.000 claims abstract description 17
210000003169 central nervous system Anatomy 0.000 claims abstract description 14
238000004519 manufacturing process Methods 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
208000006011 Stroke Diseases 0.000 claims abstract description 12
210000004556 brain Anatomy 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims abstract description 9
210000000278 spinal cord Anatomy 0.000 claims abstract description 7
230000008736 traumatic injury Effects 0.000 claims abstract description 6
208000028867 ischemia Diseases 0.000 claims description 11
230000010412 perfusion Effects 0.000 claims description 9
201000006474 Brain Ischemia Diseases 0.000 claims description 7
206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
206010008118 cerebral infarction Diseases 0.000 claims description 7
208000007536 Thrombosis Diseases 0.000 claims description 4
206010047163 Vasospasm Diseases 0.000 claims description 4
230000003073 embolic effect Effects 0.000 claims description 4
230000001575 pathological effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 13
239000008280 blood Substances 0.000 claims 3
210000004369 blood Anatomy 0.000 claims 3
102000047174 Disks Large Homolog 4 Human genes 0.000 abstract description 62
108700019745 Disks Large Homolog 4 Proteins 0.000 abstract description 61
210000002569 neuron Anatomy 0.000 abstract description 32
238000000034 method Methods 0.000 abstract description 21
230000006378 damage Effects 0.000 abstract description 18
208000027418 Wounds and injury Diseases 0.000 abstract description 11
101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 abstract description 9
230000008569 process Effects 0.000 abstract description 6
230000000302 ischemic effect Effects 0.000 abstract description 5
238000011282 treatment Methods 0.000 abstract description 5
208000037906 ischaemic injury Diseases 0.000 abstract description 4
230000002427 irreversible effect Effects 0.000 abstract description 2
101150069842 dlg4 gene Proteins 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 43
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 43
231100000419 toxicity Toxicity 0.000 description 23
230000001988 toxicity Effects 0.000 description 23
230000000694 effects Effects 0.000 description 20
230000000692 anti-sense effect Effects 0.000 description 19
230000004913 activation Effects 0.000 description 15
238000001994 activation Methods 0.000 description 15
238000011068 loading method Methods 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
230000007812 deficiency Effects 0.000 description 14
229940046166 oligodeoxynucleotide Drugs 0.000 description 14
102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 11
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 9
230000006870 function Effects 0.000 description 9
108091006146 Channels Proteins 0.000 description 8
230000002950 deficient Effects 0.000 description 8
230000004941 influx Effects 0.000 description 8
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 8
230000037361 pathway Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
102100024117 Disks large homolog 2 Human genes 0.000 description 7
101710185758 Disks large homolog 2 Proteins 0.000 description 7
101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000003119 immunoblot Methods 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 5
102000003678 AMPA Receptors Human genes 0.000 description 5
108090000078 AMPA Receptors Proteins 0.000 description 5
108020004202 Guanylate Kinase Proteins 0.000 description 5
206010029350 Neurotoxicity Diseases 0.000 description 5
238000000692 Student's t-test Methods 0.000 description 5
206010044221 Toxic encephalopathy Diseases 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 5
102000006638 guanylate kinase Human genes 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
231100000189 neurotoxic Toxicity 0.000 description 5
230000002887 neurotoxic effect Effects 0.000 description 5
238000001543 one-way ANOVA Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 4
102100022263 Disks large homolog 3 Human genes 0.000 description 4
101710185762 Disks large homolog 3 Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 4
102000000079 Kainic Acid Receptors Human genes 0.000 description 4
108010069902 Kainic Acid Receptors Proteins 0.000 description 4
KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 4
108020001305 NR1 subfamily Proteins 0.000 description 4
102000034570 NR1 subfamily Human genes 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
238000000540 analysis of variance Methods 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 4
210000003618 cortical neuron Anatomy 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
231100000228 neurotoxicity Toxicity 0.000 description 4
230000007135 neurotoxicity Effects 0.000 description 4
229960000715 nimodipine Drugs 0.000 description 4
239000002243 precursor Substances 0.000 description 4
208000020431 spinal cord injury Diseases 0.000 description 4
238000010186 staining Methods 0.000 description 4
238000012353 t test Methods 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000004958 brain cell Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000009460 calcium influx Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000002461 excitatory amino acid Effects 0.000 description 3
239000003257 excitatory amino acid Substances 0.000 description 3
231100000318 excitotoxic Toxicity 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000016273 neuron death Effects 0.000 description 3
230000007996 neuronal plasticity Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
230000006916 protein interaction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000946 synaptic effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
108020004491 Antisense DNA Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 2
101000902097 Mus musculus Disks large homolog 4 Proteins 0.000 description 2
102000002247 NADPH Dehydrogenase Human genes 0.000 description 2
108010014870 NADPH Dehydrogenase Proteins 0.000 description 2
102000038100 NR2 subfamily Human genes 0.000 description 2
108020002076 NR2 subfamily Proteins 0.000 description 2
XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 2
DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003816 antisense DNA Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000001201 calcium accumulation Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
238000010217 densitometric analysis Methods 0.000 description 2
238000001739 density measurement Methods 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
238000002073 fluorescence micrograph Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
229950006874 kainic acid Drugs 0.000 description 2
230000013016 learning Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003094 perturbing effect Effects 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
229950010357 tetrodotoxin Drugs 0.000 description 2
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
ZFLWDHHVRRZMEI-ZDUSSCGKSA-N (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid methyl ester Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)[C@H]1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-ZDUSSCGKSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
239000000774 AMPA receptor agonist Substances 0.000 description 1
UEFODXNXUAVPTC-VEVYYDQMSA-N Asp-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UEFODXNXUAVPTC-VEVYYDQMSA-N 0.000 description 1
239000012583 B-27 Supplement Substances 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
WZJLBUPPZRZNTO-CIUDSAMLSA-N Cys-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N WZJLBUPPZRZNTO-CIUDSAMLSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010058558 Hypoperfusion Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000000470 PDZ domains Human genes 0.000 description 1
108050008994 PDZ domains Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010038912 Retinoid X Receptors Proteins 0.000 description 1
102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 1
101710184528 Scaffolding protein Proteins 0.000 description 1
SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 1
108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
ZUUDNCOCILSYAM-KKHAAJSZSA-N Thr-Asp-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZUUDNCOCILSYAM-KKHAAJSZSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000000668 effect on calcium Effects 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000009483 enzymatic pathway Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000035611 feeding Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000003126 immunogold labeling Methods 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002909 kainic acid receptor agonist Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000015654 memory Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
108010056582 methionylglutamic acid Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000007472 neurodevelopment Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
230000005064 nitric oxide mediated signal transduction Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000009758 senescence Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083618 sodium nitroprusside Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
231100000747 viability assay Toxicity 0.000 description 1
238000003026 viability measurement method Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2273622A 1999-06-02 1999-06-02 Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales Expired - Lifetime CA2273622C (fr)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
CA2273622A CA2273622C (fr)	1999-06-02	1999-06-02	Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales
US10/208,374 US7595297B2 (en)	1999-06-02	2002-07-30	Method of reducing injury to mammalian cells
US10/930,192 US7510824B2 (en)	1999-06-02	2004-08-31	Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US11/894,818 US7846897B2 (en)	1999-06-02	2007-08-20	Agents for reducing injury to mammalian cells
US12/392,988 US8071548B2 (en)	1999-06-02	2009-02-25	Method of reducing injury to mammalian cells
US12/557,884 US8648043B2 (en)	1999-06-02	2009-09-11	Method of reducing injury to mammalian cells
US13/286,071 US20120302504A1 (en)	1999-06-02	2011-10-31	Method Of Reducing Injury To Mammalian Cells
US14/279,243 US20150190459A1 (en)	1999-06-02	2014-05-15	Method Of Reducing Injury To Mammalian Cells
US15/292,062 US20170239316A1 (en)	1999-06-02	2016-10-12	Method Of Reducing Injury To Mammalian Cells
US15/956,563 US20180369319A1 (en)	1999-06-02	2018-04-18	Method of Reducing Injury to Mammalian Cells
US16/578,318 US20200222492A1 (en)	1999-06-02	2019-09-21	Method of Reducing Injury to Mammalian Cells

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2273622A CA2273622C (fr)	1999-06-02	1999-06-02	Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales

Publications (2)

Publication Number	Publication Date
CA2273622A1 CA2273622A1 (fr)	2000-12-02
CA2273622C true CA2273622C (fr)	2012-03-20

Family

ID=30774266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2273622A Expired - Lifetime CA2273622C (fr)	1999-06-02	1999-06-02	Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales

Country Status (1)

Country	Link
CA (1)	CA2273622C (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6942981B1 (en)	1999-05-14	2005-09-13	Arbor Vita Corporation	Method of determining interactions with PDZ-domain polypeptides
AU5011200A (en) *	1999-05-14	2000-12-05	Arbor Vita Corporation	Molecular interactions in hematopoietic cells
US7595297B2 (en)	1999-06-02	2009-09-29	Michael Tymianski	Method of reducing injury to mammalian cells
US7510824B2 (en)	1999-06-02	2009-03-31	Nono Inc.	Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2001087285A2 (fr) *	2000-05-12	2001-11-22	The Johns Hopkins University	Inhibition de l'interaction de l'antisens psd93 et psd95 avec des recepteurs de nnos et nmda
US20020045590A1 (en)	2000-10-23	2002-04-18	Yuanxiang Tao	Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors
CA2505479A1 (fr) *	2002-11-14	2004-06-03	Arbor Vita Corporation	Interactions moleculaires dans des neurones

1999
- 1999-06-02 CA CA2273622A patent/CA2273622C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2273622A1 (fr)	2000-12-02

Legal Events

Date	Code	Title	Description
2003-11-05	EEER	Examination request
2019-08-05	MKEX	Expiry	Effective date: 20190603

Publication	Publication Date	Title
US8648043B2 (en)	2014-02-11	Method of reducing injury to mammalian cells
Mandela et al.	2006	The norepinephrine transporter and its regulation
Guttmann et al.	2001	Specific proteolysis of the NR2 subunit at multiple sites by calpain
Shirao et al.	2001	Clustering and anchoring mechanisms of molecular constituents of postsynaptic scaffolds in dendritic spines
Rammes et al.	1997	Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway
Kumaran et al.	2002	Lamin A/C speckles mediate spatial organization of splicing factor compartments and RNA polymerase II transcription
Dreyer et al.	2004	Nitric oxide synthase (NOS)-interacting protein interacts with neuronal NOS and regulates its distribution and activity
Zagon et al.	1991	Zeta (ξ), a growth-related opioid receptor in developing rat cerebellum: identification and characterization
JP2008500266A (ja)	2008-01-10	Ａｍｐａ受容体エンドサイトーシスの阻害剤を用いた神経細胞反応のモジュレート方法
Bray et al.	2002	A role for the human sperm glycine receptor/Cl− channel in the acrosome reaction initiated by recombinant ZP3
De Camilli et al.	2000	Synapses
Hannan et al.	1998	Structural compartments within neurons: developmentally regulated organization of microfilament isoform mRNA and protein
JP6253596B2 (ja)	2017-12-27	アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
US8268795B2 (en)	2012-09-18	Emergence of a R-type CA2+ channel (CAV 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
Bredt	1996	Targeting nitric oxide to its targets
JP2022505101A (ja)	2022-01-14	Ｎｍｄａ受容体媒介毒性を調節するための新規の方法
JP2015514966A5 (fr)	2017-03-23
Yuen et al.	2008	Postsynaptic density-95 (PSD-95) and calcineurin control the sensitivity of N-methyl-D-aspartate receptors to calpain cleavage in cortical neurons
Lin et al.	2001	The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering
Niewenhuis et al.	1987	Calmodulin inhibitors protect against cadmium-induced testicular damage in mice
Zhu et al.	2025	Activation of the NRF2 signaling pathway mitigates arthrofibrosis by suppressing myofibroblast ferroptosis through oxidative stress regulation
Gao et al.	2010	Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro
AU2012272550B2 (en)	2017-06-01	Prevention and treatment of acute inflammatory conditions
US7915255B2 (en)	2011-03-29	Metabolism-modulating agents and uses therefor
WO2011104309A1 (fr)	2011-09-01	Composés pour le traitement de l'inflammation et de la neutropénie